23,350
-0.64%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NeoPharm Co
Its shares trade on KOSDAQ under the ticker 092730.KQ. It has been listed since 30 January 2007. In the fiscal year to 31 December 2025, it reported revenue of ₩132.18bn and net income of ₩27.82bn. At that date it held total assets of ₩217.81bn and shareholders' equity of ₩195.36bn.
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Care Products
- Listed since
- 30 Jan 2007
- Website
- neopharm.co.kr/ko/default.do ↗
Leadership
Pay as last reported
- Mr. Byeong Cheol YimChairman
- Mr. Yang Su KimChief Executive Officer, Director
- Mr. Yun KimAssistant Managing Director
- Ms. Wu Jae YimDirector
- Mr. Dong Jin ChoiNon-Executive Independent Director
- Mr. Gi Yeong HongNon-Executive Independent Director
- Mr. Hak Yeong KimNon-Executive Independent Director
- Mr. Chun Mo AhnIR Contact Officer, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NeoPharm's ATOPALM brand offers daily care for sensitive skin in South Korea.
- Derma:B provides comprehensive skincare solutions including BB creams and sun protectors.
- ZEROID targets damaged skin barriers with hypopallergenic cleansers and creams.
Weaknesses
- NeoPharm's product range is limited to cosmetics and health products in South Korea.
- The company relies on OEM manufacturing for skin drugs without expanding into new markets.
- NeoPharm's brand portfolio lacks international recognition beyond South Korea.
Opportunities
- Expanding ATOPALM into international markets could increase global market share.
- Derma:B's anti-aging products can target aging populations in developed countries.
- ZEROID's hypoallergenic products align with growing demand for sensitive skin solutions.
Threats
- Competition from established cosmetic brands in South Korea poses a market threat.
- Regulatory changes in the Consumer Staples sector could impact product approvals.
- Economic downturns in South Korea may reduce consumer spending on cosmetics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.